We need your help! Has CancerModels.Org saved you time or effort?

Please take 15 minutes to fill in a survey and help EMBL-EBI make the case for why open data resources are critical to life science research.

Survey link: https://www.surveymonkey.com/r/QGFMBH8

Date of submission: 27/05/2022

Prostate Adenocarcinoma

TM00298

Model characterisation

Provided by

The Jackson laboratory

View data at JAXContact JAX

License: EMBL-EBI

Patient / Tumour Metadata

  • Patient Sex
    male
  • Patient Age
    Not Provided
  • Patient Ethnicity
    Hispanic
  • Tumour Type
    Primary
  • Cancer Grade
    GG1:5,GG2:5,GG3:
  • Cancer Stage
    Not provided
  • Primary Site
    prostate gland
  • Collection Site
    prostate gland

PDX model engraftment

PDX model engraftment
HOST STRAIN NAMESITETYPEMATERIALMATERIAL STATUSPASSAGE
nsg
Not ProvidedHeterotopicSurgical Resection (fragment)Not Provided1

Model quality control

Model quality control
TECHNIQUEDESCRIPTIONPASSAGE
Histology, Ki67 Ihc, Cd45 Ihc, Str AnalysisThe histology of the engrafted tumor retains morphologic features of the primary patient tumor as assessed by a Board Certified Pathologist. IHC for human Ki67 validates that the tumor cells are actively dividing and are of human origin. IHC for CD45 and cytokeratin (AE1/AE3) rules out a xenograft-associated lymphocytic tumor. STR analysis validates provenance of engrafted tumor.Not provided

Immune markers

Immune markers
SAMPLE IDMMRMSIMutations per mbTMBPloidy
PR1996F336P0Not provided
High
Not provided
29.88
Not provided

Model treatment

Model treatment
DRUGDOSEPASSAGERESPONSE
Cisplatin
ChEMBLPubChem
2.0 mg/kg
1
Progressive Disease
Docetaxel
ChEMBLPubChem
10.0 mg/kg
1
Progressive Disease
Dextrose Monohydrate
PubChem
5.0 ml/kg
1
Progressive Disease